Toggle Nav
mobile icon
My Cart
Close
  • Menu
  • Setting

Bcr-Abl

Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

8 Items

per page
  1. Nilotinib(AMN-107)
    A8232 Nilotinib(AMN-107)
     1 Citation
    Target: Bcr-Abl
    Summary: Bcr-Abl kinase inhibitor,selective
      ≥26.5 mg/mL
  2. Bosutinib (SKI-606)
    A2149 Bosutinib (SKI-606)
     1 Citation
    Target: Bcr-Abl|Src
    Summary: Potent Abl/Src kinases
      ≥26.5 mg/mL
  3. Imatinib Mesylate (STI571)
    A1805 Imatinib Mesylate (STI571)
    Target: PDGFR|c-Kit|Bcr-Abl
    Summary: Abl/c-kit/PDGFR inhibitor
      ≥29.5 mg/mL
  4. Saracatinib (AZD0530)
    A2133 Saracatinib (AZD0530)
     3 Citation
    Target: Src
    Summary: Src/Abl inhibitor,potent and selective
      ≥27.1 mg/mL
  5. Ponatinib (AP24534)
    A5467 Ponatinib (AP24534)
     1 Citation
    Target: VEGFR|PDGFR|Bcr-Abl|FGFR|Src
    Summary: pan-BCR-ABL inhibitor,multi-kinase inhibitor
      ≥53.3 mg/mL
  6. GNF 5
    A8604 GNF 5
    Target: Bcr-Abl
    Summary: Bcr-Abl inhibitor
  7. GZD824
    B1402 GZD824
    Target: Bcr-Abl
    Summary: Bcr-Abl inhibitor,novel orally bioavailable
      ≥36.25 mg/mL
  8. DCC-2036 (Rebastinib)
    B1404 DCC-2036 (Rebastinib)
    Target: FLT3|Bcr-Abl|Tie-2|KDR
    Summary: Bcr-Abl inhibitor
      ≥27.7 mg/mL

8 Items

per page